Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Voloridge Investment Management LLC

Voloridge Investment Management LLC cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 147,238 shares of the company's stock after selling 87,533 shares during the quarter. Voloridge Investment Management LLC owned about 0.23% of Kymera Therapeutics worth $5,923,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Blue Trust Inc. grew its holdings in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after acquiring an additional 270 shares during the period. Summit Investment Advisors Inc. lifted its position in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after acquiring an additional 406 shares in the last quarter. KBC Group NV lifted its position in Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after buying an additional 752 shares in the last quarter. State of Wyoming purchased a new position in Kymera Therapeutics during the fourth quarter worth approximately $45,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Kymera Therapeutics by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company's stock worth $552,000 after buying an additional 1,311 shares in the last quarter.

Kymera Therapeutics Stock Down 3.8%

KYMR traded down $1.14 on Friday, hitting $29.12. 115,448 shares of the company traded hands, compared to its average volume of 566,440. The company has a 50 day moving average of $28.63 and a 200-day moving average of $35.89. Kymera Therapeutics, Inc. has a 12-month low of $19.45 and a 12-month high of $53.27. The stock has a market capitalization of $1.90 billion, a PE ratio of -12.45 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company's revenue was up 114.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.69) EPS. On average, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on KYMR shares. HC Wainwright raised their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Bank of America dropped their price objective on Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a research note on Monday, May 12th. Stifel Nicolaus initiated coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price objective for the company. Citigroup initiated coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $52.00 price target on shares of Kymera Therapeutics in a report on Monday, May 12th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $55.25.

Insiders Place Their Bets

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at approximately $2,064,510. This trade represents a 2.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This represents a 3.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,659 shares of company stock valued at $324,567. Corporate insiders own 16.01% of the company's stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.